EO 14370
Increasing Medical Marijuana and Cannabidiol Research
HealthcareGovernment Reform
Ad Space (leaderboard)
Summary
This executive order directs federal agencies to increase medical marijuana and cannabidiol (CBD) research and expand the research infrastructure. It references a 2023 FDA review supporting marijuana's medical use for pain, nausea, and anorexia, and a pending Department of Justice proposal to reschedule marijuana from Schedule I to Schedule III of the Controlled Substances Act.
Key Points
- 1The order aims to improve federal research infrastructure for medical marijuana and hemp-derived cannabinoid products, citing their use by millions of Americans and potential health benefits.
- 2It references a 2023 FDA determination of credible scientific support for marijuana's medical use and an HHS recommendation to reschedule marijuana to Schedule III, with a Department of Justice proposed rule pending administrative review.
- 3The order addresses gaps in medical guidance caused by decades of federal drug control policy, noting that 40 states have legalized medical marijuana programs but federal Schedule I classification has limited research and left patients without adequate prescribing guidance.
This summary is for informational purposes only. It may not capture all nuances of the executive order. Always refer to the official text for authoritative information.
Ad Space (rectangle)